• DiscoveryProbe™ FDA-approved Drug Library: Practical Solu...

  2026-02-03

  This article provides a scenario-driven, evidence-based exploration of how the DiscoveryProbe™ FDA-approved Drug Library (SKU L1021) streamlines cell viability, proliferation, and cytotoxicity assays for biomedical researchers. By addressing common laboratory challenges and leveraging recent scientific literature, it demonstrates how SKU L1021 enables robust drug repositioning, reliable pharmacological target identification, and improved workflow efficiency.

• JC-1 Mitochondrial Membrane Potential Assay Kit: Advanced...

  2026-02-03

  Explore the JC-1 Mitochondrial Membrane Potential Assay Kit for precise ΔΨm measurement and advanced mitochondrial function analysis. This article offers a scientific deep dive into innovative applications and assay optimization, providing a perspective distinct from standard apoptosis assay guides.

• JC-1 Mitochondrial Membrane Potential Assay Kit: Next-Gen...

  2026-02-02

  Explore the JC-1 Mitochondrial Membrane Potential Assay Kit for advanced mitochondrial membrane potential detection in apoptosis and immunomodulatory cancer research. Uncover unique mechanistic links between ΔΨm measurement and emerging immunotherapy strategies.

• Rucaparib (AG-014699): Systems-Level Insights in PARP Inh...

  2026-02-02

  Explore Rucaparib (AG-014699), a potent PARP inhibitor, through a systems biology lens—revealing advanced mechanisms in DNA damage response and radiosensitization. This article uniquely integrates cell death pathways and transporter dynamics, offering new directions for cancer biology research.

• DiscoveryProbe™ FDA-approved Drug Library: Data-Driven So...

  2026-02-01

  This article addresses key experimental bottlenecks faced by biomedical researchers using cell viability, proliferation, or cytotoxicity assays, showcasing how the DiscoveryProbe™ FDA-approved Drug Library (SKU L1021) reliably overcomes them. Scenario-driven analysis, supported by recent literature and comparative data, illustrates why this high-throughput, clinically validated compound collection is a preferred choice for robust, reproducible screening workflows.

• Benzyl Quinolone Carboxylic Acid: Selective M1 Muscarinic...

  2026-01-31

  Benzyl Quinolone Carboxylic Acid (BQCA) is a highly selective positive allosteric modulator of the M1 muscarinic acetylcholine receptor, providing robust potentiation of acetylcholine signaling. This article details atomic evidence, benchmarks, and protocol parameters for BQCA in cognitive function modulation and Alzheimer's disease research.

• 3-Aminobenzamide: Potent PARP Inhibitor for Translational...

  2026-01-30

  3-Aminobenzamide (PARP-IN-1) from APExBIO empowers researchers to precisely dissect poly (ADP-ribose) polymerase biology across oxidative stress, diabetic nephropathy, and antiviral models. Its low toxicity, robust solubility, and validated performance in cellular and animal systems set a new standard for PARP inhibition workflows.

• DiscoveryProbe™ FDA-approved Drug Library: A Gold Standar...

  2026-01-30

  The DiscoveryProbe FDA-approved Drug Library provides a rigorously curated collection of 2,320 clinically approved bioactive compounds, supporting high-content and high-throughput screening workflows. Its stability, mechanistic diversity, and regulatory coverage make it a premier resource for drug repositioning and pharmacological target identification.

• Benzyl Quinolone Carboxylic Acid (BQCA): Selective M1 Rec...

  2026-01-29

  Benzyl Quinolone Carboxylic Acid (BQCA) is a highly selective positive allosteric modulator of the M1 muscarinic acetylcholine receptor, enabling robust potentiation of acetylcholine signaling. BQCA demonstrates >100-fold selectivity for M1 over other subtypes, increases acetylcholine potency up to 129-fold, and is validated for brain-penetrant activity in vivo. Its quantitative and mechanistic benchmarks make it a keystone tool for Alzheimer’s disease and cognitive function research.

• 3-Aminobenzamide (PARP-IN-1): Redefining PARP Inhibition ...

  2026-01-29

  Explore the multifaceted scientific impact of 3-Aminobenzamide, a potent PARP inhibitor, in dissecting immunometabolic pathways and viral-host interactions. This article delivers advanced insights and experimental frameworks, setting it apart from standard guides.

• Acifran: Structural Insights and Next-Gen Tools for Lipid...

  2026-01-28

  Explore how Acifran, a selective HM74A/GPR109A and GPR109B agonist, drives innovation in lipid metabolism research by enabling structural, mechanistic, and translational advances. Discover unique perspectives on lipid signaling pathway modulation and metabolic disorder research with this advanced compound.

• Azilsartan Medoxomil Monopotassium: Potent Angiotensin Re...

  2026-01-28

  Azilsartan medoxomil monopotassium (TAK 491) delivers exceptional potency and selectivity as an angiotensin II receptor type 1 antagonist, making it a top choice for blood pressure regulation and cardiovascular disease research. This article provides actionable experimental workflows, comparative advantages, and expert troubleshooting tips to maximize data quality in essential hypertension studies. See how APExBIO’s high-purity compound empowers reproducible, cutting-edge investigations.

• DiscoveryProbe™ FDA-approved Drug Library: Advancing Mech...

  2026-01-27

  Unlock the full potential of the DiscoveryProbe FDA-approved Drug Library for advanced mechanistic studies, rare disease modeling, and translational drug repositioning. Explore how this FDA-approved bioactive compound library enables high-throughput and high-content screening with scientific rigor and novel research applications.

• Benzyl Quinolone Carboxylic Acid (BQCA): Selective M1 Mus...

  2026-01-27

  Benzyl Quinolone Carboxylic Acid (BQCA) is a highly selective positive allosteric modulator of the M1 muscarinic acetylcholine receptor. As a tool compound, it delivers robust, dose-dependent potentiation of acetylcholine signaling—enabling precise investigation of cognitive function and Alzheimer's disease pathways.

• LGK-974 (SKU B2307): Reliable PORCN Inhibition for Wnt Pa...

  2026-01-26

  Addressing common experimental challenges in Wnt signaling assays, this article dissects real-world lab scenarios where LGK-974 (SKU B2307) offers reproducible, nanomolar-precision inhibition of Porcupine (PORCN). Drawing from peer-reviewed literature and APExBIO’s validated product data, we highlight how LGK-974 enables sensitive, low-cytotoxicity modulation of Wnt/β-catenin activity across various cancer models.

15651 records 1/1044 page Next 12345 下5页 Last page